A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters

Recombinant influenza virus neuraminidase (NA) is a promising broadly protective influenza vaccine candidate. However, the recombinant protein alone is not sufficient to induce durable and protective immune responses and requires the coadministration of immunostimulatory molecules. Here, we evaluated the immunogenicity and cross-protective potential of a recombinant influenza virus N2 neuraminidase vaccine construct, adjuvanted with a toll-like receptor 9 (TLR9) agonist (CpG 1018® adjuvant), and alum. The combination of CpG 1018 adjuvant and alum induced a balanced and robust humoral and T-cellular immune response against the NA, which provided protection and reduced morbidity against homologous and heterologous viral challenges in mouse and hamster models. This study supports Syrian hamsters as a useful complementary animal model to mice for pre-clinical evaluation of influenza virus vaccines.

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2024-09-05
DOI
https://doi.org/10.1016/j.vaccine.2024.126269
Citations
12
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
4.64

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters

Madhumathi Loganathan, Dihua Yu, Irene Hoxie, Kirill Vasilev et al.
12 citations
Vaccine
Influenza Virus Research Studies
4.64
article

A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters

Madhumathi Loganathan, Dihua Yu, Irene Hoxie, Kirill Vasilev, Jordan J. Clark, Ben Francis, S. Mark Tompkins, Gabriele Neumann, Lizheng Guan, Florian Krammer, Chunyang Gu, Yoshihiro Kawaoka, John D. Campbell, Shufang Fan, Kaitlyn Bushfield
article en
12 citations

Abstract

Recombinant influenza virus neuraminidase (NA) is a promising broadly protective influenza vaccine candidate. However, the recombinant protein alone is not sufficient to induce durable and protective immune responses and requires the coadministration of immunostimulatory molecules. Here, we evaluated the immunogenicity and cross-protective potential of a recombinant influenza virus N2 neuraminidase vaccine construct, adjuvanted with a toll-like receptor 9 (TLR9) agonist (CpG 1018® adjuvant), and alum. The combination of CpG 1018 adjuvant and alum induced a balanced and robust humoral and T-cellular immune response against the NA, which provided protection and reduced morbidity against homologous and heterologous viral challenges in mouse and hamster models. This study supports Syrian hamsters as a useful complementary animal model to mice for pre-clinical evaluation of influenza virus vaccines.

VaccineVol. 42(24)
University of Wisconsin–Madison (US), University of Georgia (US), Dynavax Technologies (United States) (US), The University of Tokyo (JP), Icahn School of Medicine at Mount Sinai (US)
National Institute of Allergy and Infectious Diseases
Good health and well-being, Zero hunger
Openalex Percentile: Top 4%
Influenza Virus Research Studies
4.64
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.